Detection of Protein Aggregation using Fluorescence Correlation Spectroscopy
April 25th, 2021
5.5K views
We here introduce a procedure to measure protein oligomers and aggregation in cell lysate and live cells using fluorescence correlation spectroscopy.
Overview
This article presents a detailed protocol for detecting and analyzing protein aggregation using fluorescence correlation spectroscopy (FCS) in both cell lysates and live cells. The method focuses on aggregation-prone proteins relevant to neurodegenerative diseases, specifically ALS-associated TDP25 and mutant SOD1, utilizing FCS to assess their diffusion properties and aggregation states.
Key Study Components
Area of Science
- Neurodegeneration research
- Protein biophysics
- Cell biology
- Fluorescence microscopy
Background
- Protein aggregation is a hallmark of neurodegenerative disorders such as ALS, Alzheimer's, Parkinson's, and Huntington's diseases.
- Fluorescence correlation spectroscopy (FCS) enables detection of single particles and analysis of their diffusion and aggregation states.
- Standardized procedures for FCS-based aggregation detection are not widely disseminated.
- Understanding protein aggregation dynamics is crucial for elucidating disease mechanisms.
Purpose of Study
- To provide a standardized protocol for FCS measurement of protein aggregation in cell lysates and live cells.
- To demonstrate the detection of soluble oligomers and aggregates of ALS-associated proteins.
- To analyze diffusion properties of aggregation-prone proteins using FCS.
Methods Used
- Culturing and preparing Neuro2a cells for transfection and measurement.
- Transfection of cells with GFP-tagged TDP25 or SOD1 constructs.
- Preparation of cell lysates and live cell samples for FCS analysis.
- Calibration and setup of confocal microscope-combined FCS system using Rhodamine 6G.
- FCS measurements in both cell lysates and live cells, followed by curve fitting and data analysis.
Main Results
- GFP-tagged TDP25 aggregates were detected in the soluble fraction of Neuro2a cell lysate, indicated by spikes in photon count rate during FCS.
- GFP-tagged SOD1 with ALS-associated mutation exhibited slower diffusion in live cells, suggesting aggregation or oligomerization.
- Spikes in FCS data corresponded to soluble oligomers or aggregates in lysate, while live cells showed fewer spikes but slower diffusion for mutant SOD1.
- Representative FCS curves and fitted parameters were obtained for both protein constructs.
Conclusions
- The described FCS protocol enables sensitive detection and analysis of protein aggregation in both lysates and live cells.
- FCS can distinguish between monomeric and aggregated protein species based on diffusion properties.
- This standardized approach facilitates broader application of FCS in neurodegeneration research.
Frequently Asked Questions
What is the main advantage of using FCS for protein aggregation studies?
FCS provides single-molecule sensitivity, allowing detection of both monomeric and aggregated protein species based on their diffusion properties in real time.
Which proteins were analyzed in this protocol?
The protocol focused on ALS-associated TDP25 and mutant SOD1 proteins, both tagged with GFP for fluorescence detection.
How are protein aggregates detected using FCS?
Aggregates are detected as spikes or bursts in the photon count rate during FCS measurements, indicating the passage of bright, slowly diffusing particles through the detection volume.
What are the key steps in preparing samples for FCS analysis?
Key steps include culturing and transfecting Neuro2a cells, preparing cell lysates or live cell samples, calibrating the FCS system, and performing measurements under controlled conditions.
How does the diffusion property relate to protein aggregation?
Aggregated proteins diffuse more slowly than monomeric forms, and this difference in diffusion time is quantified by FCS to assess aggregation state.
Can this FCS protocol be applied to other aggregation-prone proteins?
Yes, the protocol is adaptable to other proteins of interest, provided they can be fluorescently labeled and expressed in suitable cell systems.
What precautions should be taken during FCS measurements?
Proper calibration, careful sample preparation, and minimizing photobleaching are important for accurate FCS measurements and reliable data interpretation.
Executive Industry Relevance
Fluorescence correlation spectroscopy (FCS) enables high-sensitivity detection of protein aggregation, a critical factor in neurodegenerative disease research and early drug discovery. Quantitative measurement of diffusion properties in cell lysates and live cells supports mechanistic de-risking and target validation for aggregation-prone proteins. Integrating FCS into discovery workflows enhances predictive confidence and informs portfolio triage decisions for neurodegeneration programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of aggregation mechanisms in disease-relevant proteins.
- Supports functional target validation by distinguishing monomeric and aggregated species.
- Provides mechanistic de-risking through quantitative diffusion analysis.
- Facilitates predictive confidence in target selection for neurodegenerative indications.
Screening & Assay Development
- Prepares validated biological systems for downstream aggregation screening.
- Delivers quantitative, reproducible readouts of protein aggregation states.
- Enables assay standardization for compound evaluation targeting aggregation pathways.
- Supports scalability and platform reuse for multiple protein targets.
Translational & Preclinical Research
- Aligns aggregation measurements with disease-relevant cellular models.
- Ensures continuity from discovery through preclinical validation of aggregation-modulating agents.
- Provides risk-adjusted data for advancement decisions in neurodegeneration pipelines.
- Strengthens translational biomarker strategies by linking aggregation to functional outcomes.
Pipeline & Workflow Integration
FCS-based aggregation detection fits at the interface of early discovery and lead identification, providing actionable data for both target validation and assay development in neurodegeneration research.
- Discovery Biology: Quantifies aggregation dynamics to clarify disease mechanisms and de-risk targets.
- Screening: Supplies reproducible, quantitative aggregation metrics for compound triage.
- Analytics: Generates diffusion and brightness measurements to compare aggregation across conditions.
- Translational Research: Bridges in vitro and live cell aggregation data for preclinical continuity.
- Enterprise Reuse: Establishes a standardized, reusable platform for aggregation analysis across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in aggregation studies.
- Operational Value: Delivers standardized, reproducible, and scalable aggregation measurements.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency in neurodegeneration portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of aggregation-targeting assets.
Implementation Considerations
- Requires expertise in confocal microscopy and FCS data analysis.
- Needs access to calibrated FCS instrumentation and fluorescence labeling capabilities.
- Demands cross-team standardization for sample preparation and measurement protocols.
- Adaptable to various aggregation-prone proteins with appropriate fluorescent tags.
- Photobleaching and calibration must be carefully managed for reliable results.
Biopharma FAQs
Why does null hypothesis testing matter for FCS-based aggregation detection?
Null hypothesis testing in FCS aggregation studies ensures that observed diffusion differences are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit into FCS diffusion analysis?
Isolating variables such as protein construct or cellular context in FCS measurements enables clear attribution of aggregation effects, strengthening mechanistic insights and discovery pipeline decisions.
What do quantitative dependent variable measurements enable in FCS aggregation studies?
Quantitative measurements of diffusion time and photon count rates allow teams to distinguish monomeric from aggregated species, enabling data-driven triage and prioritization of targets or compounds.
Why are replication requirements critical for cross-functional FCS workflows?
Replication ensures that aggregation detection and diffusion measurements are reproducible across teams, supporting cross-functional collaboration and reliable advancement decisions in R&D pipelines.
What statistical analysis capabilities are required before FCS implementation?
Teams must be able to perform curve fitting, model selection, and significance testing on FCS data to validate aggregation findings and support portfolio-level decision making.
